PDS Biotech Announces Achievement of an Enrollment - GlobeNewswire

Retrieved on: 2022-03-15 11:47:52

Tags for this article:

Cancer

Medicine

Health sciences

Infectious causes of cancer

Papillomavirus

Gynaecological cancer

Carcinogens

Human papillomavirus infection

Immunotherapy

Oncology

Vulvar cancer

National Cancer Institute

Versamune

pds biotechnology corporation

Click the tags to see associated articles and topics

PDS Biotech Announces Achievement of an Enrollment - GlobeNewswire. View article details on HISWAI: https://www.globenewswire.com/news-release/2022/03/15/2403305/37149/en/PDS-Biotech-Announces-Achievement-of-an-Enrollment-Objective-in-National-Cancer-Institute-Led-Phase-2-Clinical-Trial-of-PDS0101-Based-Combination-in-Advanced-HPV-Associated-Cancers.html

Excerpt

FLORHAM PARK, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company ...

Article found on: www.globenewswire.com

View Original Article